
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has experienced a significant increase in the demand for donor organs, particularly with a 15% year-over-year growth in DCD hearts and a remarkable 44% year-over-year rise in DCD livers, contributing to a 7% overall growth in the total transplant market for hearts, livers, and lungs combined. Despite some month-over-month fluctuations, the company has demonstrated solid growth in the DCD segment, with promising trends in lung transplantation and potential for new product launches that could drive future revenue. If TransMedics achieves projected revenues of over $120 million in 4Q24, it positions the company favorably against consensus estimates for 1Q25 and the full year 2025, reflecting optimistic growth prospects.
Bears say
TransMedics Group Inc. reported a decline in organ transplant volumes, with donor after brain death (DBD) livers and hearts experiencing year-over-year decreases of 6% and 6%, respectively, alongside a monthly decline of 13% and 12%. In contrast, the donor after cardiac death (DCD) livers exhibited growth at 52% year-over-year. Additionally, despite a slight revenue estimate increase for 2026, group multiples decreased, and growing competition, along with potential changes in reimbursement and adoption rates, pose significant risks to the company's future growth and market share.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares